Bank Julius Baer & Co. Ltd Zurich Trims Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Bank Julius Baer & Co. Ltd Zurich decreased its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 18.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 47,232 shares of the biotechnology company’s stock after selling 11,028 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Arcturus Therapeutics were worth $1,489,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. SG Americas Securities LLC acquired a new stake in Arcturus Therapeutics during the third quarter worth $1,938,000. Commonwealth Equity Services LLC increased its stake in Arcturus Therapeutics by 27.7% during the third quarter. Commonwealth Equity Services LLC now owns 14,739 shares of the biotechnology company’s stock worth $377,000 after acquiring an additional 3,200 shares during the last quarter. Robeco Institutional Asset Management B.V. acquired a new stake in Arcturus Therapeutics during the third quarter worth $303,000. Stratos Wealth Partners LTD. acquired a new stake in Arcturus Therapeutics during the third quarter worth $301,000. Finally, Bank of New York Mellon Corp increased its stake in Arcturus Therapeutics by 3.9% during the third quarter. Bank of New York Mellon Corp now owns 94,427 shares of the biotechnology company’s stock worth $2,413,000 after acquiring an additional 3,587 shares during the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock opened at $26.55 on Friday. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $17.52 and a fifty-two week high of $43.81. The stock has a 50-day simple moving average of $33.73 and a 200-day simple moving average of $29.80.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($1.69) by $1.37. Arcturus Therapeutics had a negative return on equity of 18.22% and a negative net margin of 15.65%. The business had revenue of $33.99 million during the quarter, compared to the consensus estimate of $64.14 million. On average, research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.83 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. William Blair reissued an “outperform” rating on shares of Arcturus Therapeutics in a research note on Friday, March 8th. Citigroup lifted their price objective on Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, February 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a research note on Wednesday, March 20th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $61.33.

Insider Activity

In other Arcturus Therapeutics news, COO Pad Chivukula sold 17,435 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $35.02, for a total transaction of $610,573.70. Following the completion of the sale, the chief operating officer now directly owns 473,448 shares of the company’s stock, valued at approximately $16,580,148.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 13.80% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.